Dr. Yibin Wang is currently a full Professor of Molecular Medicine in the David Geffen School of Medicine at UCLA.

 He is the Chair of Cardiovascular Theme at UCLA, the Vice Chair for Research and Director of the Division of Molecular Medicine in the Department of Anesthesiology and Perioperative Medicine.  

Dr. Wang received his Ph.D. in molecular genetics and cell biology from Baylor College of Medicine and post-doctoral training in neurobiology and molecular cardiology at The Scripps Research Institute and University of California at San Diego. Dr. Wang’s research mainly focuses on genetic and molecular mechanisms of heart failure and metabolic disorders. His lab has made major advances in uncovering stress-signaling mechanisms in the pathogenesis of heart failure, and revealed functional importance amino acids catabolism in heart failure and metabolic disorders.  In addition, his lab reported novel regulatory mechanisms in cardiac transcriptome reprogramming involving RNA splicing regulation and non-coding RNA mediated epigenetic modulation.  

He has published over 190 peer-reviewed manuscripts in scientific journals, including Cell, Nature Medicine, Cell Metabolism, Cell Systems, Cell Stem Cell, Journal of Clinical Investigation, Circulation, Circulation Research, and PNAS. The Google-scholar H-index for all his publications is 69

Dr. Wang received an Established Investigator Award from American Heart Association in 2005. He was awarded the title of Chang-Jiang Scholar from Minister of Education of China in 2009, and Chinese National Expert for “Thousand Talent Plan” in 2011 and was the recipient of Thomas Smith Memorial Lecture award at 2016 American Heart Association Scientific Session.  He currently serves in the editorial board of Circulation Research, Journal of Biological Chemistry, and Journal of Molecular and Cellular Cardiology. Dr. Wang is also a member of the Scientific Advisory Board for Keystone Symposium and Institute of Biomedical Sciences of Academy Sinica, Taiwan.  Dr. Wang holds honorary and visiting professorships in Beijing Union Medical University, Shanghai Jiaotong University, Zhejiang University and Wuhan University. Dr. Wang is the principal investigator of several NIH and DoD grants. He has served in BCVS leadership committees and Scientific Session Program Committees for AHA.  He served in more than 30 Ph.D. thesis committees, and is currently the course master and Vice Chair of the Molecular, Cellular and Integrated Physiology Ph.D. program at UCLA.  He has served as consultant for several major pharmaceutical companies, including Merck, Pfizer, GSK, Eli Lilly, and Amgen, and biotech start-ups. He holds four patents licensed by different companies.